Immunotherapy for the treatment of cancer
Methods for the treatment of cancer using double negative (DN) T cells are described. The DNTs may be used for the treatment of chemotherapy-resistant cancers such as recurring or relapsing acute myeloid leukemia (AML). The use of allogenic DNTs, such as those derived from healthy donors, that do not exhibit toxicity towards normal host tissues and the complications associated with graft-versus-host-disease, is also described..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Europäisches Patentamt - (2019) vom: 31. Dez. Zur Gesamtaufnahme - year:2019 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
ZHANG LI [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2019-12-31, Last update posted on www.tib.eu: 2022-07-14, Last updated: 2023-02-09 |
|---|
| Patentnummer: |
US10517937 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA006221955 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA006221955 | ||
| 003 | DE-627 | ||
| 005 | 20230504082732.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210531s2019 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA006221955 | ||
| 035 | |a (EPA)US10517937 | ||
| 035 | |a (EPA)55303743 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a ZHANG LI |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunotherapy for the treatment of cancer |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2019-12-31, Last update posted on www.tib.eu: 2022-07-14, Last updated: 2023-02-09 | ||
| 520 | |a Methods for the treatment of cancer using double negative (DN) T cells are described. The DNTs may be used for the treatment of chemotherapy-resistant cancers such as recurring or relapsing acute myeloid leukemia (AML). The use of allogenic DNTs, such as those derived from healthy donors, that do not exhibit toxicity towards normal host tissues and the complications associated with graft-versus-host-disease, is also described. | ||
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a LEE JONG BOK |4 aut | |
| 700 | 0 | |a CHEN BRANSON |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2019) vom: 31. Dez. |
| 773 | 1 | 8 | |g year:2019 |g day:31 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/55303743/publication/US10517937A1?q=US10517937 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2019 |b 31 |c 12 |
| 951 | |a AR | ||
| 952 | |j 2019 |b 31 |c 12 | ||